Page 9 - Read Online

Page 202 Fenton et al. Cancer Drug Resist 2018;1:200-3 I http://dx.doi.org/10.20517/cdr.2018.19

In conclusion, a lack of response or resistance to anti-cancer therapies, whichever you prefer to call it,
is the key obstacle that needs to be overcome to improve therapy outcomes in patients diagnosed with
advanced disease who depend on systemic therapies. You will see from the conference abstracts and the
contributions to this Special Issue that a wide spectrum of aspects of response and resistance in cancer
were covered at the conference. We would like to thank all the contributors to this Special Issue and hope
that you, the reader, will find the topic and content both interesting and useful. Finally, we encourage you
to join us at the follow-up 2nd BACR Conference on Response and Resistance in Cancer Therapy, which is
planned for 15th to 17th June 2020 at the University of Kent in Canterbury, UK.

DECLARATIONS
Authors’ contributions
All authors contributed to the writing and revision of the article and read and approved the final version.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, et al. Bladder cancer. Lancet 2016;388:2796-810.
2. Harbeck N, Gnant M. Breast cancer. Lancet 2017;389:1134-50.
3. Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol 2017;35:975-83.
4. Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA 2017;317:2532-42.
5. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018;553:446-54.
6. Lim SH, Johnson PWM. Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood 2018;131:1679-88.
7. Pierorazio PM, Albers P, Black PC, Tandstad T, Heidenreich A, et al. Non-risk-adapted surveillance for stage I testicular cancer: critical
review and summary. Eur Urol 2018;73:899-907.
8. Steeg PS. Targeting metastasis. Nat Rev Cancer 2016;16:201-18.
9. Paul CD, Mistriotis P, Konstantopoulos K. Cancer cell motility: lessons from migration in confined spaces. Nat Rev Cancer
2017;17:131-40.
10. Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer 2018;18:533-48.
11. Sopik V, Rosen B, Giannakeas V, Narod SA. Why have ovarian cancer mortality rates declined? Part III. Prospects for the future.
Gynecol Oncol 2015;138:757-61.
12. Erben V, Bhardwaj M, Schrotz-King P, Brenner H. Metabolomics biomarkers for detection of colorectal neoplasms: a systematic review.
Cancers (Basel) 2018;10:E246.
13. Li J, Han X, Yu X, Xu Z, Yang G, et al. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular
carcinoma: circulating tumor cells and circulating tumor DNA. J Exp Clin Cancer Res 2018;37:213.
14. Loke SY, Lee ASG. The future of blood-based biomarkers for the early detection of breast cancer. Eur J Cancer 2018;92:54-68.